Search results for "TUMOR-BEARING MICE"

showing 1 items of 1 documents

Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.

2018

Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved survival in experimental cancer. However, the underlying mechanisms have not yet been fully uncovered. Methods The effects of blocking activin receptor type 2 (ACVR2) ligands on both muscle and non‐muscle tissues were investigated in a preclinical model of cancer cachexia using a recombinant soluble ACVR2B (sACVR2B‐Fc). Treatment with sACVR2B‐Fc was applied either only before the tumour formation or with continued treatment both before and after tumour formation. The potential roles of muscle and non‐muscle tissues in cancer cachexia were investigated in order to understand th…

MaleTUMOR-BEARING MICElcsh:Diseases of the musculoskeletal systemCachexiaprotein synthesisActivin Receptors Type IIMDSCphysical activityAcute phase responseKaplan-Meier EstimateACTIVATIONActivinMiceNeoplasmsOrthopedics and Sports MedicineTOR Serine-Threonine Kinasesactivinlcsh:Human anatomyII RECEPTORSRecombinant ProteinsProtein TransportLivermyostatinPROTEIN-SYNTHESISSKELETAL-MUSCLECytokinessyöpätauditInflammation MediatorsACUTE-PHASE RESPONSE3122 CancersINHIBITIONlcsh:QM1-695acute phase responsePhysiology (medical)Cell Line TumorAnimalsHumansMuscle SkeletalActivin; Acute phase response; MDSC; Myostatin; Physical activity; Protein synthesis; Orthopedics and Sports Medicine; Physiology (medical)Physical activityMyeloid-Derived Suppressor CellsMyostatinXenograft Model Antitumor AssaysDisease Models AnimalACTIVIN-APHYSICAL-ACTIVITY3121 General medicine internal medicine and other clinical medicineproteiinitEXPERIMENTAL CANCER CACHEXIAlcsh:RC925-935Protein synthesislihassurkastumasairaudetBiomarkersSpleenJournal of cachexia, sarcopenia and muscle
researchProduct